Search

News Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment –⁠ interactive video case study

The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is now becoming a reality. From chemotherapy, through immunochemotherapy, to the use of molecules targeting apoptotic pathways of tumor cells, the prognosis for patients has markedly improved. However, the wide therapeutic spectrum also brings its own specifics and complications, and the correct sequencing of treatment lines and their selection for each individual is necessary, considering the nature of CLL, overall condition, and comorbidities.

Source: Chronic Lymphocytic Leukemia 5. 8. 2022

News The Importance of Vitamin D for the Proper Function of the Immune System

The relationship between vitamin D and the immune system has been known for nearly 30 years, but only in recent years have we gained new insights that explain and further refine the physiological role of vitamin D in the functioning of the human immune system.

Source: GI, colic and microbiome 29. 3. 2021

News Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF

The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant von Willebrand factor (rvWF) in 23 patients with severe von Willebrand disease (vWD), who had previously been treated either on-demand (during spontaneous bleeding episodes) or had been on prophylaxis with plasma-derived vWF (pdvWF).

Source: Hemophilia 4. 11. 2024

News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds

A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.

Source: Wound Healing 4. 8. 2022

News Safety of Long-Term Therapy with Bevacizumab in Oncological Patients

The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study published in the journal The Oncologist deals specifically with its long-term safety and tolerability in patients with various types of solid tumors.

Source: Oncological Treatment 21. 4. 2022

News Noonan's Syndrome –⁠ History and Present

The genetically determined syndrome linking congenital heart defect with a typical facial phenotype is named after Jacqueline Noonan, a pediatric cardiologist who practiced in the second half of the 20th century. She was the first to recognize and describe it. In the following text, we will briefly introduce it and discuss the circumstances of its discovery.

Source: Growth Disorders 30. 11. 2020

News Inhibition of Sclerostin in Osteoporosis Therapy

Romosozumab, a subcutaneously administered antibody against sclerostin, is one of the most potent osteoanabolics and appears to be a highly effective modality in the treatment of postmenopausal women's osteoporosis. Essential information about the mechanism of action, insights from completed pivotal studies, and practical recommendations for romosozumab treatment are summarized in the following brief overview.

Source: Osteoporosis – Trends in Sequential Therapy 27. 9. 2023

News Currently on the Issue of Interchangeability of Preparations with Levothyroxine in Practice

Levothyroxine (LT4) in oral form is the standard therapy for patients with hypothyroidism. Given the legislative possibility of generic substitution and the number of original and generic preparations containing LT4, its substitution is possible, though not recommended. What are the practical conclusions?

Source: Thyroid Disorders 17. 7. 2023

News Human Papillomavirus in Adults –⁠ HPV Does Not Choose Gender

A significant part of the population is exposed to human papillomaviruses (HPV) throughout their lives. In recent years, there has been a global effort to increase vaccination coverage not only among children and adolescents who have not yet been vaccinated but also among adult women and men who could benefit from it, including those who have likely already encountered HPV.

Source: Regular Vaccination 31. 5. 2024

News Treatment of Glaucoma: Without Preservatives for Everyone?

A comprehensive report by Professor John Thygesen from the University Hospital in Copenhagen analyzes patient groups for whom preservative-free antiglaucoma medications are particularly suitable. In conclusion, he suggests that if there are no price differences, widespread treatment with preservative-free preparations is preferable.

Source: Treatment of Glaucoma 20. 8. 2020

News When the Cause of Hematomas in Anticoagulated Patients is Not Anticoagulants –⁠ Case Report

Not every bleeding during anticoagulation, especially if within the therapeutic range, can be attributed to this treatment. Particularly in older individuals and the presence of typical extensive hematomas, it is necessary to consider another cause, such as acquired hemophilia A. The following case report illustrates how such a case can be detected and what can be done to improve the patient's prognosis.

Source: Acquired Hemophilia 18. 11. 2022

News Dabigatran vs. Warfarin: What and Why Do Patients Prefer?

The key to adherence to long-term anticoagulant therapy is primarily the satisfaction of patients with the set therapy. The RE-SONANCE study published in April 2021 compared patient satisfaction with anticoagulant treatment using the direct oral anticoagulant (DOAC) dabigatran versus vitamin K antagonists (VKAs). What were the findings?

Source: Anticoagulant Treatment 1. 7. 2021

News Spiolto Respimat System –⁠ Innovation for Easier Inhalation

Inhalation delivery is the most preferred method of drug administration in chronic obstructive pulmonary disease and bronchial asthma. The effectiveness of therapy is also conditioned by the correct inhalation technique. The aim of the following article is a brief comparison of inhalation systems, focusing on a new addition to the group of aerosol inhalers.

Source: COPD 16. 3. 2020

News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.

Source: Intestinal Inflammations 21. 8. 2022

News Innovative Form of Levothyroxine Ensures Accurate Dosing for Patients

In the treatment of hypothyroidism, precise dosing of replacement therapy is critical. An innovative formulation of levothyroxine has been developed to meet the updated, stricter standards of regulatory authorities, thereby ensuring the desired therapeutic effect.

Source: Thyroid Disorders 8. 6. 2022